Lucid Diagnostics names John Palumbo to board of directors

Lucid Diagnostics Inc. (NASDAQ: LUCD) appointed John R. Palumbo to its board of directors, effective September 22, 2025, according to a company statement.

Palumbo brings 40 years of healthcare executive experience spanning early-stage ventures, growth companies, and Fortune 100 enterprises. He has guided two companies through initial public offerings and led transformation initiatives at large organizations.

Most recently, Palumbo served as executive chairman of ValueHealth, a value-based surgical platform, where he led a recapitalization in 2018 and a strategic investment in 2022. He previously held senior executive roles at AmerisourceBergen Corporation (NYSE: ABC), where he led the provider business unit and its consulting and technology divisions, expanding it into a multibillion-dollar platform serving health systems nationwide.

Palumbo also served as chief operating officer at Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX), overseeing the company's transformation from a physician dispensing business into an electronic medical record platform. He was president of I-trax Inc., building it into a national leader in on-site primary care, pharmacy, and population health services for Fortune 500 employers.

He began his career at Shared Medical Systems, where he led National Health Services and Outsourcing Services before the company was acquired by Siemens Healthineers AG in 2000.

Palumbo currently serves on boards of PM Pediatrics, ivWatch, and Qless, and chairs the advisory board of Brado, an AI-driven engagement platform serving health systems.

Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM). The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer.

You May Also Be Interested In

• AeroVironment adds former Leonardo DRS CEO to its board
• Prairie Operating Co. names new CEO and CFO amid leadership changes
• OSR Health launches CVR program to reward long-term shareholders